Revolution Medicines (RVMD) Files Rule 144 for 150,000-Share Sale

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) notice reports a proposed sale under Rule 144 of 150,000 common shares through Morgan Stanley Smith Barney. The filing shows the shares were acquired and will be sold on 09/11/2025 via exercise of stock options, with cash payment at exercise. The filing lists an aggregate market value of $6,067,500 for the shares and reports 186,933,190 shares outstanding, implying the 150,000-share block represents about 0.08% of outstanding common stock. The filer also disclosed a prior sale on 06/16/2025 of 4,289 shares for gross proceeds of $170,830.87. The notice contains broker details and the filer’s signature attestations required under Rule 144.

Positive

• Full disclosure of transaction details including acquisition method (exercise), payment type (cash), broker name, and planned sale date
• Transaction size is small relative to outstanding shares (150,000 shares ≈ 0.08% of 186,933,190 shares outstanding)
• Previous recent sale disclosed (4,289 shares sold on 06/16/2025 for $170,830.87), showing consistency in reporting

Negative

• Insider sale planned for 150,000 shares, which may be viewed as insider liquidity though no motive is stated
• Filing lacks the filer’s name and full contact details in the provided excerpt (CIK/CCC and submission contact fields are blank in content)

Insights

Securities Analyst

TL;DR: Insider exercise and planned sale of 150,000 RVMD shares is modest relative to total float and is disclosed per Rule 144 requirements.

The filing documents a standard Rule 144 notice where shares were acquired by exercising stock options and are scheduled for sale through Morgan Stanley Smith Barney on 09/11/2025. The 150,000 shares equal roughly 0.08% of the stated 186.9 million shares outstanding, indicating the transaction is small versus company size. The filing also reports a prior small sale of 4,289 shares on 06/16/2025. This is a routine insider liquidity event; materiality appears limited based on the stated numbers.

Corporate Governance Expert

TL;DR: The filing fulfills Rule 144 disclosure obligations for an option exercise and planned sale, with required attestations present.

The form shows compliant disclosure: acquisition date and nature (exercise of stock options), payment method (cash), broker information, and a representation that the filer is not aware of undisclosed material adverse information. The presence of a recent small prior sale is noted. From a governance perspective, the document provides the key elements regulators and investors expect for transparency of insider sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	150000	6067500.00	186933190	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/11/2025	Exercise of Stock Options	Issuer			150000	09/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
STEPHEN M. KELSEY 700 Saginaw Drive Redwood City CA 94063	Common	06/16/2025	4289	170830.87

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the RVMD Form 144?

The filing reports a proposed sale of 150,000 Revolution Medicines common shares to be sold on 09/11/2025, acquired by exercise of stock options and paid in cash.

How much are the 150,000 RVMD shares valued at in the filing?

The filing lists an aggregate market value of $6,067,500 for the 150,000 shares.

Who is the broker handling the sale of RVMD shares?

The sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Has the filer sold any RVMD shares recently?

Yes. The filer sold 4,289 shares on 06/16/2025 for gross proceeds of $170,830.87.

What portion of RVMD’s outstanding shares does 150,000 represent?

Based on the filing’s 186,933,190 shares outstanding, 150,000 shares represent about 0.08% of outstanding common stock.